Display options
Cite
Yarlagadda A, Taylor JH, Hampe CS, et al. GAD65 antibodies, chronic psychosis, and type 2 diabetes mellitus. Innov Clin Neurosci. 2011;8(8):34-6
Yarlagadda, A., Taylor, J. H., Hampe, C. S., Alfson, E., & Clayton, A. H. (2011). GAD65 antibodies, chronic psychosis, and type 2 diabetes mellitus. Innovations in clinical neuroscience, 8(8), 34-6.
Yarlagadda, Atmaram, et al. "GAD65 antibodies, chronic psychosis, and type 2 diabetes mellitus." Innovations in clinical neuroscience vol. 8,8 (2011): 34-6.
Yarlagadda A, Taylor JH, Hampe CS, Alfson E, Clayton AH. GAD65 antibodies, chronic psychosis, and type 2 diabetes mellitus. Innov Clin Neurosci. 2011 Aug;8(8):34-6. PMID: 21922068; PMCID: PMC3173753.
Copy Download .nbib Format: NLM
Share it on

Innov Clin Neurosci. 2011 Aug;8(8):34-6.

GAD65 antibodies, chronic psychosis, and type 2 diabetes mellitus.

Innovations in clinical neuroscience

Atmaram Yarlagadda, Jerome H Taylor, Christiane S Hampe, Elizabeth Alfson, Anita H Clayton

Affiliations

  1. Department of Psychiatry and Neurobehavioral Sciences, Charlottesville, Virginia, USA. [email protected]

PMID: 21922068 PMCID: PMC3173753

Abstract

Glutamic acid decarboxylase is the rate-limiting enzyme in the production of gamma aminobutyric acid, an inhibitory neurotransmitter. Autoantibodies to the glutamic acid decarboxylase 65 isoform have been associated with chronic psychotic disorders and are found in neurons and pancreatic islets. Blood samples were collected from normal controls (n=16), individuals with chronic psychosis with type 2 diabetes mellitus (n=3), and patients with chronic psychosis without diabetes (n=8). No differences were found between any of the groups for frequency of positive glutamic acid decarboxylase 65Ab samples (98th percentile of a healthy control group) or in mean values of glutamic acid decarboxylase 65Ab. Sample size was likely too small to detect differences if they do exist.

Keywords: GAD65 autoantibodies; GAD65Ab; Glutamic acid decarboxylase; diabetes; psychosis

References

  1. Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2115-9 - PubMed
  2. Ann Neurol. 1998 Aug;44(2):194-201 - PubMed
  3. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8337-41 - PubMed
  4. J Neural Transm (Vienna). 2003 Jul;110(7):803-12 - PubMed
  5. Neuron. 1991 Jul;7(1):91-100 - PubMed
  6. J Clin Endocrinol Metab. 1999 Feb;84(2):643-8 - PubMed
  7. Diabetes. 1994 Jan;43(1):161-5 - PubMed
  8. Biochim Biophys Acta. 1999 Jul 8;1450(3):191-231 - PubMed
  9. Prog Neuropsychopharmacol Biol Psychiatry. 2006 May;30(3):512-5 - PubMed
  10. Diabetes. 1993 Mar;42(3):484-95 - PubMed
  11. Psychiatry (Edgmont). 2007 Jun;4(6):57-9 - PubMed
  12. Biol Psychiatry. 2004 Oct 1;56(7):476-82 - PubMed
  13. Cancer. 2003 Jun 1;97(11):2806-13 - PubMed
  14. J Clin Endocrinol Metab. 2000 Dec;85(12):4671-9 - PubMed
  15. J Clin Invest. 1992 Jan;89(1):283-92 - PubMed
  16. Schizophr Res. 2008 Oct;105(1-3):287-8 - PubMed
  17. J Comp Neurol. 1994 May 22;343(4):566-81 - PubMed
  18. Nature. 1990 Sep 13;347(6289):151-6 - PubMed

Publication Types

Grant support